Compare CVS Health Corp (CVS) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Quantumscape Corp — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while Quantumscape Corp trades at $4.67 (market cap $2.78B). The key difference: CVS Health Corp is far larger — about 40.5× Quantumscape Corp's market cap, and CVS Health Corp pays a 3.02% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Quantumscape Corp for 37 Days on average.
| CVS | QS | |
|---|---|---|
Market Cap | $112.49B | $2.78B |
Volume | 8,467,392 | 11,236,221 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $18.44 |
52-Week Low | $70.08 | $4.52 |
Typical Hold Time | 83 Days | 37 Days |
Enterprise Value | $174.83B | $1.99B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
QuantumScape (QS) trades at $4.58, down 1.51% on the day, with a bearish technical outlook and no current revenue generation. The company reported a net loss of $435.05 million in 2025 and faces significant execution risks as it develops solid-state battery technology. Analyst sentiment is cautious with 73% hold ratings, though the consensus price target of $10.35 suggests potential upside if commercialization milestones are met.
QS represents a high-risk, high-reward opportunity in the pre-revenue EV battery space. The primary investment thesis hinges on successful commercialization of solid-state batteries by 2029, but competition and execution delays pose substantial risks. Current negative ROE of -39.08% and cash burn require careful monitoring of funding runway and partnership developments with automotive manufacturers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
